Design, synthesis, and biological activity of non-amidine factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units

被引:31
作者
Haginoya, N
Kobayashi, S
Komoriya, S
Yoshino, T
Nagata, T
Hirokawa, Y
Nagahara, T
机构
[1] Daiichi Pharmaceut Co Ltd, Med Chem Res Lab, Edogawa Ku, Tokyo 1348630, Japan
[2] Daiichi Pharmaceut Co Ltd, New Prod Res Lab 2, Edogawa Ku, Tokyo 1348630, Japan
关键词
factor Xa inhibitor; pyridine N-oxide; 2-carbamoylthiazole; tetrahydrothiazolopyridine;
D O I
10.1016/j.bmc.2004.08.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Based on the both of results for X-ray studies of tetrahydrothiazolopyridine derivative 1c and FXV673, we synthesized a series of thiazol-5-ylpyridine derivatives containing pyridine N-oxide and 2-carbamoylthiazole units to optimize the S4 binding element. N-Oxidation of thiazol-5-ylpyridine increased the anti-fXa activity more than 10-fold independent on the position of N-oxide. The 4-pyridine N-oxide derivatives 3a and 3d excelled over the tetrahydrothiazolopyridine 1b in potency. 2-Methylpyridine N-oxide 3d exhibited 49-fold selectivity over thrombin. Our modeling study proposed a binding mode that the pyridine N-oxide ring of 3a stuck into the 'cation hole', and the oxide anion of 3a occupied in the almost same space to that of FXV673. From observations of the SAR and modeling studies, we suggested the possibilities that the formation of hydrogen bond with the oxide anion in the 'cation hole' and the affinity of cationic pyridine ring to S4 subsite were responsible for increase in anti-fXa activity. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5579 / 5586
页数:8
相关论文
共 23 条
[1]  
ASHIMORI A, 1990, CHEM PHARM BULL, V38, P2446
[2]   Development of orally active oxytocin antagonists: Studies on 1-(1-{4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2-methoxybenzoyl}piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines [J].
Bell, IM ;
Erb, JM ;
Freidinger, RM ;
Gallicchio, SN ;
Guare, JP ;
Guidotti, MT ;
Halpin, RA ;
Hobbs, DW ;
Homnick, CF ;
Kuo, MS ;
Lis, EV ;
Mathre, DJ ;
Michelson, SR ;
Pawluczyk, JM ;
Pettibone, DJ ;
Reiss, DR ;
Vickers, S ;
Williams, PD ;
Woyden, CJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (12) :2146-2163
[3]  
DONDONI A, 1986, SYNTHESIS-STUTTGART, P757
[4]   Optimization of the β-aminoester class of factor Xa inhibitors.: Part 2:: Identification of FXV673 as a potent and selective inhibitor with excellent in vivo anticoagulant activity [J].
Guertin, KR ;
Gardner, CJ ;
Klein, SI ;
Zulli, AL ;
Czekaj, M ;
Gong, Y ;
Spada, AP ;
Cheney, DL ;
Maignan, S ;
Guilloteau, JP ;
Brown, KD ;
Colussi, DJ ;
Chu, V ;
Heran, CL ;
Morgan, SR ;
Bentley, RG ;
Dunwiddie, CT ;
Leadley, RJ ;
Pauls, HW .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (12) :1671-1674
[5]   Facile methods for preparation of thiazolopyridine and tetrahydrothiazolopyridine derivatives [J].
Haginoya, N ;
Komoriya, S ;
Osanai, K ;
Yoshino, T ;
Nagata, T ;
Nagamochi, M ;
Muto, R ;
Yamaguchi, M ;
Nagahara, T ;
Kanno, H .
HETEROCYCLES, 2004, 63 (07) :1555-1561
[6]   Orally active factor Xa inhibitors:: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives [J].
Haginoya, N ;
Kobayashi, S ;
Komoriya, S ;
Hirokawa, Y ;
Furugori, B ;
Nagahara, T .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (11) :2935-2939
[7]  
HAGINOYA N, 2004, IN PRESS J MED CHEM, V47
[8]   N,N-dialkylated 4-(4-arylsulfonylpiperazine-l-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)benzamidines as potent factor Xa inhibitors [J].
Jia, ZJ ;
Su, T ;
Zuckett, JF ;
Wu, YH ;
Goldman, EA ;
Li, WH ;
Zhang, PL ;
Clizbe, LA ;
Song, YH ;
Bauer, SM ;
Huang, WR ;
Woolfrey, J ;
Sinha, U ;
Arfsten, AE ;
Hutchaleelaha, A ;
Hollenbach, SJ ;
Lambing, JL ;
Scarborough, RM ;
Zhu, BY .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (09) :2073-2078
[9]   1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors.: Part 2:: A survey of P4 motifs [J].
Jia, ZJ ;
Wu, YH ;
Huang, WR ;
Zhang, PL ;
Clizbe, LA ;
Goldman, EA ;
Sinha, U ;
Arfsten, AE ;
Edwards, ST ;
Alphonso, M ;
Hutchaleelaha, A ;
Scarborough, RM ;
Zhu, BY .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (05) :1221-1227
[10]   1-(2-naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors.: Part 3:: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors [J].
Jia, ZZ ;
Wu, YH ;
Huang, WR ;
Zhang, PL ;
Song, YH ;
Woolfrey, J ;
Sinha, U ;
Arfsten, AE ;
Edwards, ST ;
Hutchaleelaha, A ;
Hollennbach, SJ ;
Lambing, JL ;
Scarborough, RM ;
Zhu, BY .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (05) :1229-1234